Increased serum cutaneous T cell-attracting chemokine (CCL27) levels in patients with atopic dermatitis and psoriasis vulgaris. 2003

Takashi Kakinuma, and Hidehisa Saeki, and Yuichiro Tsunemi, and Hideki Fujita, and Noriko Asano, and Hiroshi Mitsui, and Yayoi Tada, and Motoshi Wakugawa, and Takahiro Watanabe, and Hideshi Torii, and Mayumi Komine, and Akihiko Asahina, and Koichiro Nakamura, and Kunihiko Tamaki
Department of Dermatology, University of Tokyo, Tokyo, Japan.

BACKGROUND Both atopic dermatitis (AD) and psoriasis vulgaris (PsV) are characterized as chronic and relapsing inflammatory skin diseases associated with various immunologic abnormalities. Cutaneous T cell-attracting chemokine (CTACK; CCL27) is a member of the CC chemokine family and a functional ligand for CC chemokine receptor 10. It is selectively expressed in skin and attracts CC chemokine receptor 10-expressing skin-homing memory T cells. The epidermal keratinocyte is a main source of CTACK, suggesting the involvement of various inflammatory skin diseases. OBJECTIVE The purpose of this investigation was to clarify whether CTACK produced by keratinocytes is detected in the sera of patients with AD and PsV and to examine the correlation between the serum CTACK levels and disease activity of patients with AD and PsV. METHODS We measured the serum CTACK levels in 50 patients with AD, 30 patients with PsV, and 22 healthy control subjects. We also divided 50 patients with AD into 3 groups (ie, those with mild, moderate, and severe disease) and compared them among 3 categories. Moreover, we compared the serum CTACK levels of patients with AD and PsV with clinical or laboratory data. Immunohistochemical staining of CTACK and IFN-induced protein of 10 kd (IP-10; CXCL10) was performed on the lesional skin of patients with AD and PsV. RESULTS The serum CTACK levels in patients with AD and PsV were significantly higher than those in healthy control subjects. The serum CTACK levels in patients with AD significantly correlated with scoring atopic dermatitis (SCORAD) scores, serum soluble IL-2 receptor levels, serum soluble E-selectin levels, serum thymus and activation-regulated chemokine levels, and serum macrophage-derived chemokine levels. Serum CTACK levels in patients with PsV significantly correlated with the serum IP-10 levels but not with the Psoriasis Area and Severity Index score. Immunohistochemical staining showed CTACK was strongly expressed in lesional ke-ratinocytes of patients with AD and PsV, whereas IP-10 was strongly expressed in lesional keratinocytes of patients with PsV and focally in those with AD. CONCLUSIONS These results suggest that CTACK might be one of the important chemokines for the pathogenesis of AD and PsV.

UI MeSH Term Description Entries
D007150 Immunohistochemistry Histochemical localization of immunoreactive substances using labeled antibodies as reagents. Immunocytochemistry,Immunogold Techniques,Immunogold-Silver Techniques,Immunohistocytochemistry,Immunolabeling Techniques,Immunogold Technics,Immunogold-Silver Technics,Immunolabeling Technics,Immunogold Silver Technics,Immunogold Silver Techniques,Immunogold Technic,Immunogold Technique,Immunogold-Silver Technic,Immunogold-Silver Technique,Immunolabeling Technic,Immunolabeling Technique,Technic, Immunogold,Technic, Immunogold-Silver,Technic, Immunolabeling,Technics, Immunogold,Technics, Immunogold-Silver,Technics, Immunolabeling,Technique, Immunogold,Technique, Immunogold-Silver,Technique, Immunolabeling,Techniques, Immunogold,Techniques, Immunogold-Silver,Techniques, Immunolabeling
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011565 Psoriasis A common genetically determined, chronic, inflammatory skin disease characterized by rounded erythematous, dry, scaling patches. The lesions have a predilection for nails, scalp, genitalia, extensor surfaces, and the lumbosacral region. Accelerated epidermopoiesis is considered to be the fundamental pathologic feature in psoriasis. Palmoplantaris Pustulosis,Pustular Psoriasis of Palms and Soles,Pustulosis Palmaris et Plantaris,Pustulosis of Palms and Soles,Psoriases
D003876 Dermatitis, Atopic A chronic inflammatory genetically determined disease of the skin marked by increased ability to form reagin (IgE), with increased susceptibility to allergic rhinitis and asthma, and hereditary disposition to a lowered threshold for pruritus. It is manifested by lichenification, excoriation, and crusting, mainly on the flexural surfaces of the elbow and knee. In infants it is known as infantile eczema. Eczema, Atopic,Eczema, Infantile,Neurodermatitis, Atopic,Neurodermatitis, Disseminated,Atopic Dermatitis,Atopic Eczema,Atopic Neurodermatitis,Disseminated Neurodermatitis,Infantile Eczema
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D012720 Severity of Illness Index Levels within a diagnostic group which are established by various measurement criteria applied to the seriousness of a patient's disorder. Illness Index Severities,Illness Index Severity
D013194 Staining and Labeling The marking of biological material with a dye or other reagent for the purpose of identifying and quantitating components of tissues, cells or their extracts. Histological Labeling,Staining,Histological Labelings,Labeling and Staining,Labeling, Histological,Labelings, Histological,Stainings
D054357 Chemokine CXCL10 A CXC chemokine that is induced by GAMMA-INTERFERON and is chemotactic for MONOCYTES and T-LYMPHOCYTES. It has specificity for the CXCR3 RECEPTOR. CXCL10 Chemokine,CXC Chemokine IP-10,Chemokine (C-X-C Motif) Ligand 10,Cytokine IP-10 Protein,IFN-gamma-Inducible Protein, 10 kDa,Interferon-Inducible Protein 10,Interferon-gamma-Inducible Protein of 10 kDa,Small Inducible Cytokine B10,gammaIP-10 Protein,CXC Chemokine IP 10,CXCL10, Chemokine,Chemokine IP-10, CXC,Chemokine, CXCL10,Cytokine IP 10 Protein,IFN gamma Inducible Protein, 10 kDa,IP-10 Protein, Cytokine,Interferon Inducible Protein 10,Interferon gamma Inducible Protein of 10 kDa,gammaIP 10 Protein
D054425 Chemokine CCL27 A CC-type chemokine with specificity for CCR10 RECEPTORS. It is constitutively expressed in the skin and may play a role in T-CELL trafficking during cutaneous INFLAMMATION. CCL27 Chemokine,CTACK Chemokine,Cutaneous T-Cell-Attracting Chemokine,ESkine,Small Inducible Cytokine A27,CCL27, Chemokine,Chemokine, CCL27,Chemokine, CTACK,Chemokine, Cutaneous T-Cell-Attracting,Cutaneous T Cell Attracting Chemokine,T-Cell-Attracting Chemokine, Cutaneous

Related Publications

Takashi Kakinuma, and Hidehisa Saeki, and Yuichiro Tsunemi, and Hideki Fujita, and Noriko Asano, and Hiroshi Mitsui, and Yayoi Tada, and Motoshi Wakugawa, and Takahiro Watanabe, and Hideshi Torii, and Mayumi Komine, and Akihiko Asahina, and Koichiro Nakamura, and Kunihiko Tamaki
March 2006, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology,
Takashi Kakinuma, and Hidehisa Saeki, and Yuichiro Tsunemi, and Hideki Fujita, and Noriko Asano, and Hiroshi Mitsui, and Yayoi Tada, and Motoshi Wakugawa, and Takahiro Watanabe, and Hideshi Torii, and Mayumi Komine, and Akihiko Asahina, and Koichiro Nakamura, and Kunihiko Tamaki
July 2005, Rheumatology (Oxford, England),
Takashi Kakinuma, and Hidehisa Saeki, and Yuichiro Tsunemi, and Hideki Fujita, and Noriko Asano, and Hiroshi Mitsui, and Yayoi Tada, and Motoshi Wakugawa, and Takahiro Watanabe, and Hideshi Torii, and Mayumi Komine, and Akihiko Asahina, and Koichiro Nakamura, and Kunihiko Tamaki
May 2004, Clinical and experimental dermatology,
Takashi Kakinuma, and Hidehisa Saeki, and Yuichiro Tsunemi, and Hideki Fujita, and Noriko Asano, and Hiroshi Mitsui, and Yayoi Tada, and Motoshi Wakugawa, and Takahiro Watanabe, and Hideshi Torii, and Mayumi Komine, and Akihiko Asahina, and Koichiro Nakamura, and Kunihiko Tamaki
January 2013, Journal of the European Academy of Dermatology and Venereology : JEADV,
Takashi Kakinuma, and Hidehisa Saeki, and Yuichiro Tsunemi, and Hideki Fujita, and Noriko Asano, and Hiroshi Mitsui, and Yayoi Tada, and Motoshi Wakugawa, and Takahiro Watanabe, and Hideshi Torii, and Mayumi Komine, and Akihiko Asahina, and Koichiro Nakamura, and Kunihiko Tamaki
January 2013, European journal of dermatology : EJD,
Takashi Kakinuma, and Hidehisa Saeki, and Yuichiro Tsunemi, and Hideki Fujita, and Noriko Asano, and Hiroshi Mitsui, and Yayoi Tada, and Motoshi Wakugawa, and Takahiro Watanabe, and Hideshi Torii, and Mayumi Komine, and Akihiko Asahina, and Koichiro Nakamura, and Kunihiko Tamaki
February 2004, The Journal of allergy and clinical immunology,
Takashi Kakinuma, and Hidehisa Saeki, and Yuichiro Tsunemi, and Hideki Fujita, and Noriko Asano, and Hiroshi Mitsui, and Yayoi Tada, and Motoshi Wakugawa, and Takahiro Watanabe, and Hideshi Torii, and Mayumi Komine, and Akihiko Asahina, and Koichiro Nakamura, and Kunihiko Tamaki
December 2018, The Journal of dermatology,
Takashi Kakinuma, and Hidehisa Saeki, and Yuichiro Tsunemi, and Hideki Fujita, and Noriko Asano, and Hiroshi Mitsui, and Yayoi Tada, and Motoshi Wakugawa, and Takahiro Watanabe, and Hideshi Torii, and Mayumi Komine, and Akihiko Asahina, and Koichiro Nakamura, and Kunihiko Tamaki
April 2024, The Journal of investigative dermatology,
Takashi Kakinuma, and Hidehisa Saeki, and Yuichiro Tsunemi, and Hideki Fujita, and Noriko Asano, and Hiroshi Mitsui, and Yayoi Tada, and Motoshi Wakugawa, and Takahiro Watanabe, and Hideshi Torii, and Mayumi Komine, and Akihiko Asahina, and Koichiro Nakamura, and Kunihiko Tamaki
January 2012, European journal of dermatology : EJD,
Takashi Kakinuma, and Hidehisa Saeki, and Yuichiro Tsunemi, and Hideki Fujita, and Noriko Asano, and Hiroshi Mitsui, and Yayoi Tada, and Motoshi Wakugawa, and Takahiro Watanabe, and Hideshi Torii, and Mayumi Komine, and Akihiko Asahina, and Koichiro Nakamura, and Kunihiko Tamaki
January 2005, Cytokine,
Copied contents to your clipboard!